Tilray Shares Slide Following Analyst Downgrade

Tilray Brands, Inc. saw its stock come under significant selling pressure in today’s session. The decline was triggered by a sharp rating cut from Zacks Investment Research, which shifted its stance on the cannabis company’s shares to “Strong Sell.” This move highlights growing concerns following the firm’s latest quarterly report and underscores the ongoing volatility within the sector. In a contrasting development, Bernstein maintained its neutral position, illustrating the divided sentiment among market observers.

Quarterly Results Present a Mixed Picture

The company’s recent financial performance lies at the heart of the divergent analyst views. Tilray’s quarterly figures revealed a stark contrast between top-line growth and bottom-line struggles.

• On the negative side, the company reported a quarterly loss per share of -$0.41. This figure was substantially worse than the analyst consensus estimate, which had projected a loss of -$0.14 per share.
• Conversely, revenue provided a brighter spot. Tilray generated $217.51 million in sales, surpassing market expectations of $211.15 million and indicating continued operational growth.

This combination of revenue strength and deepening losses points to persistent challenges in the company’s cost structure, a key hurdle on its path to profitability.

A Clash of Analyst Opinions

The investment community is clearly split in its assessment. Zacks Research’s decision to downgrade Tilray from a “Hold” to a “Strong Sell” rating reflects heightened skepticism about its near-term earnings trajectory. The firm cited the disappointing quarterly loss as a primary reason for its more bearish outlook.

Standing in opposition, Bernstein analyst Nadine Sarwat reaffirmed her “Market-Perform” rating on the same day. Data aggregators like MarketBeat and TipRanks show an average analyst recommendation hovering between “Reduce” and “Hold.” Price targets also show a wide dispersion, with MarketBeat citing an older average target near $15, while more recent data from TipRanks suggests a consensus closer to $9.50—just below the current trading level of approximately $9.90.

Should investors sell immediately? Or is it worth buying Tilray?

From Regulatory Euphoria to a Reality Check

The current price action marks a dramatic comedown from recent highs. In December 2025, Tilray’s stock experienced extreme volatility following an executive order from President Trump to reclassify marijuana from a Schedule I to a Schedule III substance.

The prospect of regulatory easing fueled a powerful rally, propelling the stock to a 52-week high of $23.20. However, market enthusiasm has since faded considerably, with the share price retracing most of those gains and consolidating in the $9 to $10 range. Zacks’ “Strong Sell” rating suggests institutional observers are now recalibrating their valuations in light of the ongoing operational losses.

Technical Outlook and Key Levels to Watch

From a chart perspective, Tilray remains well below its former peak. The current price around $9.90 sits far under the 52-week high of $23.20, though it remains notably above the yearly low of $3.51.

In the near term, the $9 level is likely to emerge as a critical support zone for the stock. For any sustained recovery to take hold, the focus will shift decisively to management’s ability to outline a credible strategy for reducing per-share losses in upcoming quarters. This operational progress is now seen as crucial, regardless of how the broader U.S. regulatory landscape continues to evolve.